Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Selcia Appoints New Director of Discovery

Published: Wednesday, October 09, 2013
Last Updated: Wednesday, October 09, 2013
Bookmark and Share
Appointment of John Davis to the role of Director of Discovery.

Selcia Limited has appointed John Davis to the newly created role of Director of Discovery.

John joins Selcia from Convergence Pharmaceuticals, where he served as Head of Biology between 2010 and 2013 and was a co-founder of the company.

Dr. Hans Fliri, chairman and CEO of Selcia Ltd., said “We are delighted that John has joined Selcia, his extensive drug discovery expertise will be a tremendous asset to our business. We have an ambitious plan to grow and further develop Selcia’s integrated drug discovery service. John’s knowledge of the international pharmaceutical and biotechnology industries will undoubtedly help us achieve that goal.”

John’s particular research interests have been focussed on cardiovascular, oncology and CNS disorders. Much of his 20 years’ drug discovery experience was gained at SmithKline Beecham and GlaxoSmithKline and encompasses a range of target classes including ion channels, GPCRs, kinases and proteases.

With his deep experience of target identification through to clinical proof of concept, John has been responsible for the discovery of 11 small molecule and biologic development candidates, and the preclinical pharmacology supporting two assets achieving positive Phase II and one product.

At GSK John was variously director of neurodegeneration research, a director of discovery technologies and director of biology for pain and epilepsy research, and was also instrumental in the formation and management of several large collaborations with universities.

John originally trained as a biochemist and has a PhD from Cambridge University. He was a research fellow at the Ludwig Institute for Cancer Research and Salk Institute for six years before joining SmithKline Beecham in 1993. He has over 100 peer reviewed publications and patents to his name.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

University of Edinburgh and Selcia in £2.5 m Bid
Edinburgh University and Selcia research new drugs to combat sleeping sickness disease.
Tuesday, February 04, 2014
Selcia Awarded GMP Certificate for Preparation and Carbon-14 Labelling of APIs for Clinical Trials
Extended capability expected to shorten the timeframe for commencement of client’s key Phase 1 clinical trials.
Thursday, December 09, 2010
Scientific News
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
Hyperstable Peptides for 'On-Demand' Drugs
These small molecules can fold into different conformations that could allow for greater flexibility in precision drug design
Drug Leads Identified to Combat Heart Disease
Using three supercomputers, researchers surveyed protein structures through accelerated molecular dynamics.
Accelerating the Path to Molecules for Medicine
Researchers convert carbon-hydrogen bonds into nitriles - converting organic molecules into components of medicines.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos